Gout Diagnosis and Management

Introduction to Gout

Gout is characterized by monosodium urate (MSU) crystal deposition in joints and soft tissues, which occurs when uric acid levels exceed the solubility threshold of approximately 6.8 mg/dL, as stated by the American College of Physicians, based on evidence from the Annals of Internal Medicine 1

The definitive diagnosis of gout requires identification of MSU crystals in synovial fluid using polarized light microscopy, according to the European League Against Rheumatism 2
The sensitivity and specificity of hyperuricemia alone for diagnosing gout is relatively low, ranging from 53% to 61%, as reported by the European League Against Rheumatism 2
The absence of hyperuricemia during an acute attack should not exclude a diagnosis of gout if clinical manifestations are suggestive, although this fact is not directly cited, it is implied by the diagnostic guidelines 2

Synovial fluid analysis is recommended whenever possible to confirm diagnosis, as suggested by the European League Against Rheumatism 2
Serum uric acid levels should preferably be determined at a distance from a gout flare for more accurate assessment, according to the European League Against Rheumatism 2
Treatment of acute gout flares should be based on clinical presentation rather than serum uric acid levels, as stated by the American College of Rheumatology, based on evidence from the Annals of the Rheumatic Diseases 4
For patients with confirmed gout, urate-lowering therapy should target serum uric acid levels below 6 mg/dL regardless of levels during acute flares, as recommended by the American College of Rheumatology, based on evidence from the Annals of the Rheumatic Diseases 4

First-line options for treating acute gout flares include colchicine (within 12 hours of flare onset), NSAIDs, or corticosteroids, as suggested by the European League Against Rheumatism 4
For patients with renal impairment, colchicine and NSAIDs should be avoided, and corticosteroids are preferred, according to the European League Against Rheumatism 4